Five years after settling, GSK is again accused of breaching the Jemperli deal.
ApexOnco Front Page
Recent articles
Arcellx and AstraZeneca take centre stage.
Global data are in the same ballpark as Chinese results presented earlier this year.
A common mutation comes into play for PRMT5 inhibition.
Early data with IDE849 look better those with Zai’s zocilurtatug pelitecan.
Investors now have more reasons to doubt Harmoni's ability to back US approval.
Tolerability could decide first-line therapy in EGFRm disease.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
